

A1
--22. (NEW) A composition comprising an isolated and purified polypeptide comprising the amino acid sequence of -16 to -1, inclusive, of SEQ ID NO:831.

23. (NEW) The polypeptide of Claim 22 comprising the amino acid sequence of SEQ ID NO:831.

24. (NEW) A method of producing the polypeptide of Claim 22, comprising the steps of:
a) culturing a host cell capable of expressing said polypeptide under conditions suitable for producing said polypeptide and
b) isolating and purifying said polypeptide produced by said host cell.--

REMARKS

Election of Claims for prosecution:

Claims 2, 3, 9, 14-16, and 18 have been cancelled without prejudice. Claims 1, 4-8, 10-13, 17, and 19-21, as well as newly added Claims 22-24, are pending in this application. Claims 22-24 are drawn to the elected group. Applicants respectfully submit that support for the newly added Claims 22-24 is replete throughout the specification. Specific support for the polypeptide of Claims 22 and 23 can be found on pages 14-15 and in SEQ ID NO:831. Applicants request consideration of Claim 24, drawn to a method of producing a polypeptide. It is the Applicants understanding that, under the Patent Office Group policy, newly added Claim 24 would have been included in the elected Group II as it relies on the subject matter of that Group. Specific support for the method of Claim 24 can be found in Example 22 (pages 101-106).

Sequence Disclosure:

The Examiner objects to the presence of nucleotide sequences in Figure 5 and elsewhere, as these sequences are allegedly not listed in the paper copy and computer readable form (CRF) of the Sequence Listing. The Examiner further objects that the sequence identifier "SEQ ID NO:X" must be used in the drawing or in the Brief Description of the Drawings.

Appln. No. : 09/471,446
Filed : December 21, 1999

Applicants respectfully request cancellation of Figure 5 in response to the Examiner's objection.

Drawings:

Applicants respectfully request cancellation of Figures 6-9, in addition to Figure 5. Applicants respectfully assert that the cancelled figures are unnecessary for understanding of the present invention. Original Figure 10 has been amended to reflect that it is now Figure 5. Figures 1-4 and newly amended Figure 5 have been corrected to comply with the Draftsperson's objections. Applicants request entry of Figures 1-5, which are included in the present response.

Specification:

Applicants request entry of the enclosed substitute specification. The substitute specification, not including the Claims or Sequence Listing, is filed in compliance with 37 CFR 1.125. No new matter has been added. A marked up copy of the original application reflecting the changes made is included in the present response. The following changes have been made to the original specification: the "Brief Description of Drawings" (pages 21-22) has been amended to reflect cancellation of Figures 5-9; the reference to Figure 10 (page 88) has been amended to reflect the change to Figure 5; the paragraph on page 150 lines 13-21 is amended to remove reference to cancellation of Figure 5; and the section titled "Example 61" (pages 159-168) has been amended to reflect cancellation of Figures 6-9.

Appln. No. : 09/471,776
Filed : December 21, 1999

Applicants respectfully submit that the present application is fully in condition for allowance and such action is earnestly solicited. If any questions remain, the Examiner is invited to contact the undersigned to resolve such questions in a timely manner. This response has been filed with a request for a one month extension of time. Please charge any additional fees, or credit overpayment to Deposit Account No. 50-1181.

Respectfully submitted,

GENSET CORPORATION

Date: 20 Nov,
2001

By: John Lucas

John Lucas, Ph.D., J.D.
Reg. No. 43,373

Certificate of Mailing

Date of Deposit: _____, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Assistant Commissioner for Patents, Box Non Fee Amendment, Washington, D.C. 20231.

Carol Johns
Signature

Carol Johns
Typed or Printed Name of Person Signing Certificate

CLEAN VERSION WITH CHANGES

In the Claims

22. A composition comprising an isolated and purified polypeptide comprising the amino acid sequence of -16 to -1, inclusive, of SEQ ID NO:831.

23. The polypeptide of Claim 22 comprising the amino acid sequence of SEQ ID NO:831.

24. A method of producing the polypeptide of Claim 22, comprising the steps of:

- a) culturing a host cell capable of expressing said polypeptide under conditions suitable for producing said polypeptide; and
- b) isolating and purifying said polypeptide produced by said host cell.